Press release
Hypercholesterolemia Pipeline: 25+ Leading Innovators Driving the Future of Cholesterol Management Therapies | DelveInsight
Hypercholesterolemia Pipeline
DelveInsight's "Hypercholesterolemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the hypercholesterolemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging hypercholesterolemia drugs, the hypercholesterolemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Hypercholesterolemia Pipeline Report
• DelveInsight's hypercholesterolemia pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for hypercholesterolemia treatment.
• The leading hypercholesterolemia companies include Innovent, Akeso Biopharma, Ahn-Gook Pharmaceuticals Co., Ltd, Jiangsu Hengrui Medicine Co., Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, LIB Therapeutics LLC, Addpharma Inc., Verve Therapeutics, Inc., Novo Nordisk, NewAmsterdam Pharma, Vaxxinity, Nyrada, Sirnaomics, HighTide Biopharma, Luye Pharma, Shandong Boan Biotechnology, CiVi Biopharma, Precision biosciences, SalioGen Therapeutics, and others are evaluating their lead assets to improve the Hypercholesterolemia treatment landscape.
• Key hypercholesterolemia pipeline therapies in various stages of development include Tafolecimab, Ebronucimab, AGT 2, SHR-1209, MK-0616, ARO-ANG 3, Lerodalcibep, PBGENE-PCSK9 candidate, CiVi 008, AD-221, VERVE-101, STP 135G, NNC 03850434, Obicetrapib, NYX 330, and others.
• In March 2025, Esperion (NASDAQ: ESPR) announced FDA alignment to initiate Phase III trials of bempedoic acid, alone and in combination with ezetimibe, for pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH). Bempedoic acid has Orphan Drug Designation for HoFH.
• In February 2025, LIB Therapeutics announced FDA acceptance of the BLA for Lerodalcibep to reduce LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD), or high-risk hypercholesterolemia, including HeFH and HoFH in individuals aged 10 and above.
• In January 2025, LIB Therapeutics published positive Phase III LIBerate-HoFH results for Lerodalcibep in The Lancet Diabetes & Endocrinology, demonstrating efficacy in a global HoFH hypercholesterolemia population.
Request a sample and discover the recent breakthroughs happening in the Hypercholesterolemia pipeline landscape @ https://www.delveinsight.com/report-store/hypercholesterolaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Hypercholesterolemia Overview
Hypercholesterolemia refers to high blood cholesterol levels, which can result from excess cholesterol production by the liver or from dietary sources such as meat, poultry, dairy, egg yolk, and fish. While cholesterol is essential for functions like cell membrane synthesis and hormone production, elevated levels can lead to coronary artery disease. Excess cholesterol forms fatty deposits in arteries, causing atherosclerosis, which narrows and hardens the arteries, increasing the risk of heart attack, angina, and stroke. Hypercholesterolemia typically has no symptoms, and the condition is diagnosed through a lipid profile test, which measures total cholesterol, LDL, HDL, and triglyceride levels.
Find out more about Hypercholesterolemia medication @ https://www.delveinsight.com/report-store/hypercholesterolaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Hypercholesterolemia Treatment Analysis: Drug Profile
Tafolecimab: Innovent
Tafolecimab, developed by Innovent, is an IgG2 fully human monoclonal antibody that targets PCSK-9 to reduce LDL-C levels. By inhibiting PCSK-9-mediated endocytosis of low-density lipoprotein receptors (LDLR), it enhances the clearance of LDL-C from the bloodstream. This results in a reduction in LDL-C levels. In June 2022, Innovent Biologics announced that China's National Medical Products Administration (NMPA) had accepted the New Drug Application (NDA) for tafolecimab (IBI306), an anti-PCSK-9 antibody, for the treatment of primary hypercholesterolemia.
Ebronucimab: Akeso Biopharma
Ebronucimab (AK102) is a promising PCSK9 inhibitor developed by Akeso Biopharma, aimed at treating acquired and inherited hyperlipidemias, including HoFH, HeFH, and hypercholesterolemia in patients with atherosclerotic cardiovascular disease. Ebronucimab works similarly to other PCSK9 inhibitors like Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), significantly lowering cholesterol levels and reducing the risk of heart attacks and strokes. It has shown more robust pharmacodynamic and efficacy results compared to these marketed PCSK9 antibodies. Ebronucimab is poised to become the first domestically developed PCSK9 inhibitor in China, targeting a large population of cardiovascular patients.
Key Hypercholesterolemia Therapies and Companies
• Tafolecimab: Innovent
• Ebronucimab: Akeso Biopharma
• VERVE-101: Verve Therapeutics
• Lerodalcibep: LIB Therapeutics
• Zodasiran: Arrowhead Pharmaceuticals
Learn more about the novel and emerging Hypercholesterolemia pipeline therapies @ https://www.delveinsight.com/report-store/hypercholesterolaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Hypercholesterolemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Scope of the Hypercholesterolemia Pipeline Report
• Coverage: Global
• Key Hypercholesterolemia Companies: Innovent, Akeso Biopharma, Ahn-Gook Pharmaceuticals Co., Ltd, Jiangsu Hengrui Medicine Co., Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, LIB Therapeutics LLC, Addpharma Inc., Verve Therapeutics, Inc., Novo Nordisk, NewAmsterdam Pharma, Vaxxinity, Nyrada, Sirnaomics, HighTide Biopharma, Luye Pharma, Shandong Boan Biotechnology, CiVi Biopharma, Precision biosciences, SalioGen Therapeutics, and others.
• Key Hypercholesterolemia Pipeline Therapies: Tafolecimab, Ebronucimab, AGT 2, SHR-1209, MK-0616, ARO-ANG 3, Lerodalcibep, PBGENE-PCSK9 candidate, CiVi 008, AD-221, VERVE-101, STP 135G, NNC 03850434, Obicetrapib, NYX 330, and others.
Dive deep into rich insights for drugs used for Hypercholesterolemia treatment; visit @ https://www.delveinsight.com/report-store/hypercholesterolaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Hypercholesterolemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hypercholesterolemia Pipeline Therapeutics
6. Hypercholesterolemia Pipeline: Late-Stage Products (Phase III)
7. Hypercholesterolemia Pipeline: Mid-Stage Products (Phase II)
8. Hypercholesterolemia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercholesterolemia Pipeline: 25+ Leading Innovators Driving the Future of Cholesterol Management Therapies | DelveInsight here
News-ID: 3976547 • Views: …
More Releases from DelveInsight
Laband Syndrome Market Outlook Poised for Scientific Attention by 2034 | DelveIn …
Laband Syndrome, also known as Zimmermann-Laband Syndrome, is an ultra-rare genetic disorder marked by gingival fibromatosis, distinctive facial features, joint hypermobility, and nail and bone abnormalities. Due to its rarity and limited clinical data, Laband Syndrome continues to pose challenges in diagnosis, treatment, and patient management. However, increasing awareness and advancements in genomic research are paving the way for better understanding and potential targeted interventions.
DelveInsight's report, Laband Syndrome - Market…
Palmar Hyperhidrosis Market Set for Strong Growth by 2034 - DelveInsight | Key P …
Palmar Hyperhidrosis, a chronic dermatological condition characterized by excessive sweating of the palms, continues to impact quality of life and psychological well-being for millions of individuals globally. Despite being non-life-threatening, the condition poses a significant psychosocial burden and often goes underdiagnosed or undertreated. The palmar hyperhidrosis market is witnessing steady evolution, driven by rising awareness, increased diagnosis rates, and the emergence of innovative treatment options including topical agents, neuromodulators, and…
Vaso-Occlusive Crisis Market Set for Significant Growth by 2034 - DelveInsight | …
Vaso-Occlusive Crisis (VOC), a severe and painful complication of sickle cell disease, poses a substantial burden on patients and healthcare systems globally. The VOC market is undergoing transformative growth, driven by the rising prevalence of sickle cell disease, increasing disease awareness, and advancements in therapeutic research. Emerging treatments focusing on reducing crisis frequency and severity, including novel small molecules, gene therapies, and anti-adhesion agents, are reshaping the treatment landscape toward…
Leigh Syndrome Market Poised for Robust Growth by 2034: Unlocking New Therapies …
Leigh Syndrome, a rare and severe mitochondrial disorder predominantly affecting infants and young children, presents significant clinical challenges due to its complex neurological manifestations and limited treatment options. Despite its rarity, Leigh syndrome has garnered increasing attention owing to advancements in genetic diagnostics and a growing understanding of mitochondrial dysfunction. The market for Leigh syndrome is undergoing a gradual transformation fueled by novel therapeutic approaches such as gene therapy, mitochondrial-targeted…
More Releases for Hypercholesterolemia
The Hypercholesterolemia Treatment Market to cling to the digitization
The Hypercholesterolemia Treatment Market is bound to witness a robust CAGR going forward. The present scenario is that of prediction of the course of treatment based on data analytics. Technology has been dominating in the form of IoMT (Internet-of-Medical-Things), AI (Artificial Intelligence), cloud computing, predictive analytics, and what not? With the proven advantage of the reduction in casualties and real-time access to the history of patients, and not to forget…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide “Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review”, H2 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension,…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
Hypercholesterolemia Market to Reflect Impressive Growth Rate by 2023
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
Hypercholesterolemia Market - Global Industry Analysis 2020
Hypercholesterolemia is an inherited condition that results in high levels of total cholesterol. Cholesterol is a fatty substance that occurs naturally in the body that can be dangerous when it builds up on artery walls. Hypercholesterolemia can cause atherosclerosis and increase your risk of heart disease called coronary artery disease. Human blood cholesterol includes of high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and very low-density lipoprotein (VLDL) cholesterol.
Get a…
